All IndicationsInfectious Disease
🦠
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
1
Companies
1
Drug Programs
1
Phase 3
0
Upcoming PDUFAs
Competitors
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| ETNB 89bio, Inc. | Pegozafermin | Phase 3 | — | — | — |
Development Stage Distribution
Phase 3
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.